These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29169562)

  • 61. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.
    Downs AM
    Br J Dermatol; 2010 Aug; 163(2):433-4. PubMed ID: 20456344
    [No Abstract]   [Full Text] [Related]  

  • 62. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapeutics: Silencing psoriasis.
    Crow JM
    Nature; 2012 Dec; 492(7429):S58-9. PubMed ID: 23254974
    [No Abstract]   [Full Text] [Related]  

  • 64. A prospective, interventional assessment of the impact of ustekinumab treatment on psoriasis-related work productivity and activity impairment.
    Beroukhim K; Danesh M; Nguyen C; Farahnik B; Levin E; Leon A; Koo J
    J Dermatolog Treat; 2016 Nov; 27(6):552-555. PubMed ID: 27052387
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in a solid organ transplanted recipient: A case report.
    Richetta A; Marraffa F; Grassi S; Aquila E; Dybala A; Aprile F; Merli M
    Australas J Dermatol; 2021 Aug; 62(3):e442-e443. PubMed ID: 33634474
    [No Abstract]   [Full Text] [Related]  

  • 66. Japanese guidance for use of biologics for psoriasis (the 2019 version).
    Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
    J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ustekinumab for the treatment of HIV psoriasis.
    Paparizos V; Rallis E; Kirsten L; Kyriakis K
    J Dermatolog Treat; 2012 Dec; 23(6):398-9. PubMed ID: 21787206
    [No Abstract]   [Full Text] [Related]  

  • 68. Extensive plaque psoriasis successfully treated with adalimumab (Humira).
    Sladden MJ; Mortimer NJ; Hutchinson PE
    Br J Dermatol; 2005 May; 152(5):1091-2. PubMed ID: 15888191
    [No Abstract]   [Full Text] [Related]  

  • 69. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 70. No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab.
    Rodríguez-Jiménez P; Chicharro P; Godoy A; Llamas-Velasco M; García M; Daudén E
    Br J Dermatol; 2017 Sep; 177(3):862-863. PubMed ID: 28508387
    [No Abstract]   [Full Text] [Related]  

  • 71. Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab.
    Amschler K; Phillip S; Mohr J; Wilsmann-Theis D; Poortinga S; Gerdes S; Mössner R
    Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155021
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Switching biologics for psoriasis.
    Ormerod AD
    Br J Dermatol; 2010 Oct; 163(4):667-9. PubMed ID: 20854399
    [No Abstract]   [Full Text] [Related]  

  • 73. Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series.
    Anzengruber F; Drach M; Maul JT; Kolios AG; Meier B; Navarini AA
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e274-e276. PubMed ID: 29356172
    [No Abstract]   [Full Text] [Related]  

  • 74. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
    Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
    J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
    [No Abstract]   [Full Text] [Related]  

  • 75. Treatment of inverse psoriasis with efalizumab.
    George D; Rosen T
    J Drugs Dermatol; 2009 Jan; 8(1):74-6. PubMed ID: 19180901
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ustekinumab biotherapy and real-time psoriasis capacitance mapping: a pilot study.
    Piérard-Franchimont C; Piérard GE
    J Biomed Biotechnol; 2012; 2012():870194. PubMed ID: 22536025
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis.
    Pinter A; Gerdes S; Papavassilis C; Reinhardt M
    J Dermatolog Treat; 2020 Dec; 31(8):769-775. PubMed ID: 31287332
    [No Abstract]   [Full Text] [Related]  

  • 78. Exacerbation of systemic lupus erythematosus in a patient with concomitant chronic plaque psoriasis treated with ustekinumab.
    Goh SW; Jamil A; Nor NM; Cader RA; Shaharir SS
    Indian J Dermatol Venereol Leprol; 2020; 86(1):68-70. PubMed ID: 31823905
    [No Abstract]   [Full Text] [Related]  

  • 79. Treatment of severe psoriasis with ustekinumab during pregnancy.
    Andrulonis R; Ferris LK
    J Drugs Dermatol; 2012 Oct; 11(10):1240. PubMed ID: 23134993
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
    Blauvelt A; Reich K; Warren RB; Szepietowski JC; Sigurgeirsson B; Tyring SK; Messina I; Bhosekar V; Oliver J; Papavassilis C; Frueh J; Langley RGB
    Br J Dermatol; 2017 Sep; 177(3):879-881. PubMed ID: 28498514
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.